Table 2. Duration of Follow-up and Age at Diagnosis of End-stage Renal Disease.
| Variable | All Participants | Nonoverweight and Nonobese Participants Only (CDC BMI <85th Percentile) | ||||
|---|---|---|---|---|---|---|
| Nonhypertensive (n = 2 650 241) | Hypertensive (n= 7997) | Total (N = 2 658 238) | Nonhypertensive (n = 2 237 231) | Hypertensive (n = 3946) | Total (N = 2 241 177) | |
| ESRD overall, No. (%) | 2147 (0.1) | 42 (0.5) | 2189 (0.1) | 1444 (0.1) | 9 (0.2) | 1453 (0.1) |
| Follow-up period, PY | 56 080 135 | 207 810 | 56 287 945 | 48 532 758 | 110 130 | 48 642 889 |
| Median follow-up (IQR), y | 19.6 (10.4-31.2) | 28.6 (13.1-36.7) | 19.6 (10.4-31.2) | 20.4 (11.1-31.9) | 30.4 (19.7-37.2) | 20.4 (11.1-31.9) |
| Age at diagnosis of ESRD, mean (SD), y | 53.0 (6.6) | 49.9 (7.2) | 52.9 (6.6) | 53.7 (6.3) | 49.7 (3.7) | 53.7 (6.3) |
| Crude incidence of ESRD cases, per 100 000 PY | 3.8 | 20.2 | 3.9 | 3.0 | 8.2 | 3.0 |
Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); CDC, Centers for Disease Control and Prevention; ESRD, end-stage renal disease; PY, person-years.